Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $39M (down 1.9% year over year) with net income of −$45M.
Q2 2026 key financials · XBRL
- Revenue
- $39M
- −1.9% YoY · +4.9% QoQ
- Net income
- −$45M
- −6.7% YoY · −440.7% QoQ
- Operating margin
- -114.4%
- Gross margin
- 32.4%
- EPS (diluted)
- −$0.14
- −7.7% YoY · −366.7% QoQ
Source: XBRL data from the PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Q2 2026 10-Q on SEC EDGAR. USD.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Six-month revenue $76.2M vs $76.9M YoY
- Gross margin 33.5% vs 17.3% YoY, based on gross profit of $25.5M vs $13.3M
- Consumables revenue $41.9M, up from $39.0M; instruments $22.6M, down from $25.2M
- Cash, equivalents, and investments $236.9M vs $279.5M at December 31, 2025
- Restructuring targeting $30M–$40M annualized operating-expense reductions by end of 2027, with approximately $2.0M charges in Q3 2026
Risk Factors
- Newly added expense-reduction risk triggered by third-quarter 2026 workforce reductions and narrowed development pipeline
- Most materially updated profitability risk: no profitability expected for remainder of 2026 despite additional July 2026 cost reductions
- Financial liquidity risk: $200.0 million 2029 Notes and $441.0 million 2030 Notes outstanding as of June 30, 2026
- Operational risk: slower Revio and Vega adoption could create obsolete inventory charges and losses on firm purchase commitments
- Regulatory risk: changing tariffs and trade barriers could raise costs and disrupt products, components, and supply chains
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.